Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Regulus Therapeutics stock

Learn how to easily invest in Regulus Therapeutics stock.

Regulus Therapeutics is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Regulus Therapeutics employs 27 staff and has a trailing 12-month revenue of around $5 million.

How to buy Regulus Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – RGLS. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Regulus Therapeutics stock price (NASDAQ: RGLS)

Use our graph to track the performance of RGLS stocks over time.

Regulus Therapeutics shares at a glance

Information last updated 2023-03-24.
Latest market close$0.79
52-week range$0.76 - $3.70
50-day moving average $1.37
200-day moving average $1.67
Wall St. target price$10.33
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.89

Buy Regulus Therapeutics stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $10,000 - $250,000+
Stocks, Bonds, Options, Mutual funds, ETFs, Futures
Get up to $600 or more
when you open and fund a new account.
E*TRADE offers commission-free stocks, access to mutual funds and advanced trading tools. Other fees apply.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Regulus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Regulus Therapeutics price performance over time

Historical closes compared with the close of $0.7929 from 2023-03-27

1 week (2023-03-22) -23.76%
1 month (2023-03-01) -41.27%
3 months (2022-12-29) -41.70%
6 months (2022-09-29) -54.95%
1 year (2022-03-29) 173.41%
2 years (2021-03-29) -42.96%
3 years (2020-03-27) 66.23%
5 years (2018-03-28) 87.36

Regulus Therapeutics financials

Revenue TTM $5 million
Gross profit TTM $-17,794,000
Return on assets TTM -37.13%
Return on equity TTM -83.46%
Profit margin 0%
Book value $2.36
Market capitalisation $17.5 million

TTM: trailing 12 months

Regulus Therapeutics share dividends

We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.

Have Regulus Therapeutics's shares ever split?

Regulus Therapeutics's shares were split on a 1:10 basis on 28 June 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.

Regulus Therapeutics share price volatility

Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $0.76 up to $3.699. A popular way to gauge a stock's volatility is its "beta".

RGLS.US volatility(beta: 1.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 1.645. This would suggest that Regulus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Regulus Therapeutics overview

Regulus Therapeutics Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. .

Frequently asked questions

What percentage of Regulus Therapeutics is owned by insiders or institutions?
Currently 3.639% of Regulus Therapeutics shares are held by insiders and 51.389% by institutions.
How many people work for Regulus Therapeutics?
Latest data suggests 27 work at Regulus Therapeutics.
When does the fiscal year end for Regulus Therapeutics?
Regulus Therapeutics's fiscal year ends in December.
Where is Regulus Therapeutics based?
Regulus Therapeutics's address is: 4224 Campus Point Court, San Diego, CA, United States, 92121
What is Regulus Therapeutics's ISIN number?
Regulus Therapeutics's international securities identification number is: US75915K3095
What is Regulus Therapeutics's CUSIP number?
Regulus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 75915K200

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site